Inhaled insulin: Overcoming barriers to insulin therapy?

British Journal of Diabetes and Vascular Disease

Volumn 6, Issue 3, 2006, Pages 103-108

  Bellary, Srikanth ^b   Barnett, Anthony H ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b NONE

Author keywords

Diabetes; Exubera ; Inhaled insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

ANTIBODY RESPONSE; ANTIBODY TITER; BODY WEIGHT DISORDER; BOLUS INJECTION; CIGARETTE SMOKING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETIC DIET; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; LONG TERM CARE; LUNG TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; WEIGHT GAIN;

EID: 33745940923     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514060060030201     Document Type: Review

References (46)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
3. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;29:335-42.
5. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. UK. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of Insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study. (UKPDS 57). Diabetes Care 2002;25:330-6.
6. Zamanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin treated diabetes. Diab Res Clin Pract 1999;46:239-46.
7. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292-8.
8. Gerber RA, Hauber AB, Bolinder B, Johnson FR. Diabetes patients' stated preference for insulin therapies: trading health for convenience. Diabetologia 2004;47(suppl 1):A274.
9. Chetty DJ, Chien YW. Novel methods of insulin delivery: an update. Crit Rev Ther Drug Carrier Syst 1998;15:629-70.
10. Byron PR. Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv Drug Deliv Rev 1990;5:107-32.
11. Gansslen M. Uber inhalation von insulin. Klin. Wochenschr 1925;4:71.
12. Wigley FW, Londono JH, Wood SH, Shipp JC, Waldman RH. Insulin across respiratory mucosae by aerosol delivery. Diabetes 1971;20:552-6.
13. Owens DR. New horizons-alternative routes for insulin therapy. Nat Rev Drug Discov 2002;1:529-40.
14. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50:1161-76.
15. Klonoff DC. Inhaled insulin. Diabetes Technol Ther 1999;1:307-13.
16. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801.
17. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997;14:63-72.
18. Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-82.
19. Kapitza C, Hompesch M, Scharling B, Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004;6:466-72.
20. Henry RR, Fountaine R, Willavize S, Fisher J, Fryburg D. Intrasubject variability of inhaled insulin comparable to subcutaneous regular insulin in patients with type 2 diabetes. Endocr Pract 2005;11(suppl 1):28-29. A884.
21. Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001;357:331-5.
22. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-7.
23. Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-5.
24. Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-62.
25. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162-7.
26. Rosenstock J, Baughman RA, Rivera-Schaub T et al. A randomised double blind, placebo controlled study of the efficacy and safety of Inhaled technosphere insulin in patients with type 2 diabetes. Diabetes 2005;54 (suppl 1):A 88 [Abstract 357].
27. Garg S, Rosenstock J, Muchmore D, De La Pena A, Sun B, Silverman B. Safety and Efficacy of pre-prandial human insulin inhalation powder (HIIP) delivered by the Lilly/Alkermes inhaled insulin delivery system versus injectable insulin in patients with type 1 diabetes. Diabetes 2005;54 (suppl 1):A89[Abstract 361].
28. De Fronzo RA, Bergenstal RM, Cefalu WT etal. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005;28:1922-8.
29. Rosenstock J. Zinman B, Murphy LJ et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143:549-58.
30. Skyler JS (For the inhaled insulin Phase 2 study group). Long term sustained efficacy and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia 2004;47(suppl 1):A311.
31. Barnett AH, Amiel SA, Hopkins D. Six month efficacy and 2-year safety of inhaled insulin as adjunctive therapy in combination with an oral agent. Diabet Med 2005;22(suppl 2):P82.
32. Dreyer M (For the inhaled insulin Phase 3 study group). Efficacy and 2 year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral monotherapy Diabetologia 2004;47(suppl 1):A44.
33. William T Cefalu, Marjana Serdarevic-Pehar, for Exubera Phase 3 study group. Long-term use of Exubera in type 2 diabetes: Observations on glycemic control, pulmonary function and anti-body formation. Diabetes 2005;54(suppl 1):A88.
34. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003;26:677-82.
35. Becker RH, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006;29:277-82.
36. Dumas R, England RD, Reise RJ, Teeter JG. Exubera is well tolerated and achieves tight glycemic control in patients with type 1 diabetes. Diabetes 2005;54(suppl 1):A87.
37. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-94.
38. Heise T, Bott S, Tusek C et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: A prospective randomized pharmacodynamic study Diabetes Care 2005;28:2161-9.
39. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23.
40. Freemantle N, Blonde L, Duhot D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427-8.
41. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001;24:1556-9.
42. Testa MA, Turner RR, Hayes JF, Scranton RE, Simonson DC. An international trial of sulfonylurea plus either metformin or inhaled insulin: Impact on quality of life and treatment satisfaction. Diabetologia 2004;47(suppl 1):A5.
43. Simonson DC, Turner RR, Hayes JF, Scranton RE, Testa MA. Improving quality of life in type 2 diabetes when inhaled insulin is added after failure on metformin: A multicenter, international trial. Diabetologia 2004;47(suppl 1):A311.
44. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002;24:552-64.
45. Bilous R. Overall satisfaction increased more with inhaled insulin than with subcutaneous insulin in type 1 diabetes. ACP J Club 2002;136:101.
46. Muller E, Maxion-Bergemann S, Bolinder B, Gerber RA, Bergemann R. EAGLE-Economic Assessment of Glycemic control and long term effects: A computer simulation model for diabetes mellitus type 1 and type 2. Diabetologia 2004;47(suppl 1):A355.